Moreover, leukemias carrying splicing factors mutations, that are intrinsically sensitive to splicing perturbations, responded to the selective PRMT5 inhibitors GSK3203591 and EPZ015666, and to their combination with the type I PRMT inhibitor MS023 both in vitro and in vivo, as confirmed by the prolonged survival of mice transplanted with serine and arginine rich splicing factor 2 (srsf2)P95HMLL-MLLT3 super elongation complex subunit (MLLT3)-transformed leukemia [118]. This evidence concerns the gene PRMT5 and leukemia.